NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
8 trialsNCT00003716 2022-05-31
Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy
Stanford University
Phase 2 Completed
NCT00553943 2018-08-23
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Lymphoma Study Association
Phase 2 Completed
NCT00867529 2018-01-02
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00324779 2015-09-25
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00057811 2014-09-19
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00799136 2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2 Completed
NCT01118845 2013-07-04
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals
Phase 2 Completed